ERBB2 and breast cancer: As for TILs, the most-studied component, it was higher in HER2+ and TNBC than in tubulointerstitial BC subtypes, as demonstrated by a secondary analysis of several clinical trials, such as FinHer (5), NeoALTTO (68), GeparQuattro (69), etc. Specifically, in a recent TNBC study (70), TME within TNBC is classified as immunoreactive subtype or “immune-cold” subtype by microdissection of tumor tissue.